These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 24200404

  • 1. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.
    Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL.
    Am J Respir Crit Care Med; 2013 Dec 01; 188(11):1294-302. PubMed ID: 24200404
    [Abstract] [Full Text] [Related]

  • 2. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma.
    Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL.
    Am J Respir Crit Care Med; 2010 Apr 15; 181(8):788-96. PubMed ID: 20056900
    [Abstract] [Full Text] [Related]

  • 3. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S.
    N Engl J Med; 2012 Mar 29; 366(13):1181-9. PubMed ID: 22455412
    [Abstract] [Full Text] [Related]

  • 4. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
    Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A.
    N Engl J Med; 2014 Jun 12; 370(24):2295-306. PubMed ID: 24918373
    [Abstract] [Full Text] [Related]

  • 5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 12; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 6. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.
    Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, Wallace D, Martin R, Phillips K, Kaine JL, Dong H, Salinger D, Stevens E, Russell CB, Chung JB.
    Arthritis Res Ther; 2013 Oct 25; 15(5):R164. PubMed ID: 24286136
    [Abstract] [Full Text] [Related]

  • 7. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.
    Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA.
    Respir Res; 2013 Sep 19; 14(1):93. PubMed ID: 24050312
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
    Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, Vexler V, Shames RS, Daclizumab Asthma Study Group.
    Am J Respir Crit Care Med; 2008 Nov 15; 178(10):1002-8. PubMed ID: 18787222
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G, Nirula A, Klekotka P.
    J Am Acad Dermatol; 2014 Dec 15; 71(6):1183-1190.e3. PubMed ID: 25313095
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K, Noonan M, Silkoff PE, Uryniak T.
    Clin Ther; 2007 Jun 15; 29(6):1013-26. PubMed ID: 17692718
    [Abstract] [Full Text] [Related]

  • 15. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
    Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ.
    N Engl J Med; 1999 Dec 23; 341(26):1966-73. PubMed ID: 10607813
    [Abstract] [Full Text] [Related]

  • 16. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L.
    Drugs Today (Barc); 2017 May 23; 53(5):283-297. PubMed ID: 28650001
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
    Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, Li D, Russell C, Newmark R, Zhang N, Chon Y, Hsu YH, Lin SL, Klekotka P.
    Am J Gastroenterol; 2016 Nov 23; 111(11):1599-1607. PubMed ID: 27481309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.